Evidence map›Paper›PMID 42254028›Full record

ReviewFrontiers in immunology2026

Research progress of

Xinyao Zhang, Qijiao Wang, Jie Li, Jing Cao, Zhijuan Guo, Ru Ji

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xinyao Zhang *Inner Mongolia Medical University, Hohhot, China.
Qijiao Wang *Inner Mongolia Medical University, Hohhot, China.
Jie LiInner Mongolia Medical University, Hohhot, China.
Jing CaoInner Mongolia Medical University, Hohhot, China.
Zhijuan GuoInner Mongolia Medical University Affiliated Cancer Hospital, Hohhot, China.
Ru JiInner Mongolia Medical University Affiliated Cancer Hospital, Hohhot, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunosuppression within the tumor microenvironment (TME) remains a major barrier to durable responses to cancer immunotherapy. CKLF-like MARVEL transmembrane domain-containing 4 (

Indexed as

ImmunotherapyMARVEL Domain-Containing ProteinsNeoplasmsTumor MicroenvironmentAnimalsB7-H1 AntigenBiomarkers, TumorHumansImmune Checkpoint InhibitorsB7-H1 AntigenBiomarkers, TumorCMTM4 protein, humanImmune Checkpoint InhibitorsMARVEL Domain-Containing ProteinsbiomarkersCMTM4immunotherapyPD-1/PD-L1tumor immune microenvironment

Identifiers

PMID42254028
PMCPMC13236942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.